Drug intelligence / Profile preview

BB-GF1

Development stage: Preclinical
Lead developer: StemRIM
Modality: Gene Silencing → Gene Therapies, Stem Cell Therapies → Cell Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies

Overview

BB-GF1 is an experimental stem cell gene therapy being developed by StemRIM for the treatment of epidermolysis bullosa (EB). Unlike the company's primary 'Regeneration-Inducing Medicine' platform, which utilizes synthetic peptides like redasemtide to mobilize endogenous stem cells, BB-GF1 employs a gene therapy approach involving the delivery of gene-modified stem cells. The therapy is designed to address the underlying genetic mutations that cause skin fragility in EB patients. As of early 2024, BB-GF1 is in the preclinical development stage, with the company actively preparing for Investigational New Drug (IND) application filings to initiate clinical trials.

Other names: StemRIM stem cell gene therapy

Beyond the preview

Go deeper on BB-GF1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB-GF1.

Explore the full profile